Shijiazhuang Yiling Pharmaceutical Co., Ltd.

XSEC:002603 Stock Report

Market Cap: CN¥28.1b

Shijiazhuang Yiling Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Shijiazhuang Yiling Pharmaceutical has been growing earnings at an average annual rate of 23.2%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 16% per year. Shijiazhuang Yiling Pharmaceutical's return on equity is 3.8%, and it has net margins of 5.1%.

Key information

23.2%

Earnings growth rate

23.2%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate16.0%
Return on equity3.8%
Net Margin5.1%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shijiazhuang Yiling Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:002603 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 248,9064543,131869
31 Dec 2310,3181,3523,319853
30 Sep 2313,1622,7073,8901,074
30 Jun 2313,7572,9203,9981,061
31 Mar 2313,7463,0813,9171,039
01 Jan 2312,5332,3633,8881,032
30 Sep 229,9511,5353,348806
30 Jun 229,7871,4283,410807
31 Mar 229,1701,1533,538763
01 Jan 2210,1171,3443,968792
30 Sep 2110,4471,4264,218802
30 Jun 2110,1921,4694,058760
31 Mar 2110,1171,4553,886731
31 Dec 208,7821,2193,441654
30 Sep 207,9251,0483,048518
30 Jun 207,3288662,973468
31 Mar 206,6097562,862437
31 Dec 195,8256072,584391
30 Sep 195,3366122,375399
30 Jun 195,0986062,260371
31 Mar 194,7845772,033338
01 Jan 194,8155992,116317
30 Sep 184,8486532,160260
30 Jun 184,5376491,911340
31 Mar 184,3476321,917262
31 Dec 174,0815411,876217
30 Sep 173,9725551,794138
30 Jun 174,0365691,9480
31 Mar 174,0505701,9550
31 Dec 163,8505331,8610
30 Sep 163,6655271,7600
30 Jun 163,5385101,6720
31 Mar 163,4394891,6000
31 Dec 153,1854301,4640
30 Sep 153,1613951,4600
30 Jun 153,0893761,4440
31 Mar 152,9803771,3960
31 Dec 142,9213541,4090
30 Sep 142,8773121,5030
30 Jun 142,8712941,5250
31 Mar 142,7112751,4620
31 Dec 132,4902441,3880
30 Sep 132,4162481,3550
30 Jun 132,1021961,2380

Quality Earnings: 002603 has high quality earnings.

Growing Profit Margin: 002603's current net profit margins (5.1%) are lower than last year (22.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002603's earnings have grown significantly by 23.2% per year over the past 5 years.

Accelerating Growth: 002603's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002603 had negative earnings growth (-85.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 002603's Return on Equity (3.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.